Epcoritamab plus R-CHOP reduced the risk of progression or death by 51% vs R-CHOP alone in newly diagnosed DLBCL.
News|Videos|December 23, 2025
Sonrotoclax (BGB-11417) Monotherapy in Patients With R/R MCL Previously Treated With a BTK Inhibitor: Results From a Phase 1/2 Study
Author(s)Luhua (Michael) Wang, MD
Michael Wang, M.D. discusses Sonrotoclax (BGB-11417) monotherapy in patients with R/R MCL previously treated with a BTK inhibitor: results from a phase 1/2 study
Advertisement
Michael Wang, M.D. discusses how, Sonrotoclax monotherapy showed strong and durable clinical activity in heavily pretreated patients with relapsed or refractory mantle cell lymphoma, with consistent benefit across high-risk subgroups. The treatment was generally well tolerated with manageable safety and a low rate of tumor lysis syndrome, supporting its potential as a promising new option in this setting.
Advertisement
Related to this article
The 19-year veteran of CU Anschutz will be the fourth director in the 41-year history of Colorado’s only NCI-designated comprehensive cancer center.
The estimated 3-year OS rate with botensilimab plus balstilimab was 48% in heavily pretreated recurrent ovarian cancer in the phase 1b C-800-01 trial.
PRV111 produced pathologic complete responses in 21 of 22 patients with noninvasive oral cancer or high-grade dysplasia.
A patient treated at the highest dose level of lira-cel to date had stable disease 90 days after infusion in a phase 1 trial in recurrent ovarian cancer.
A randomized phase 2 trial of berzosertib plus carboplatin in pretreated mCRPC stopped for futility amid fewer responses and more high-grade toxicity than the control arm.
The top 5 OncLive TV videos of the week cover insights in MDS, multiple myeloma, pancreatic cancer, colorectal cancer, and uveal melanoma.
The combination nearly doubled the confirmed response rate in the randomized phase 2 portion of HexAgon-HN, with the greatest benefit in HPV-positive disease.
Advertisement
Advertisement
Trending on OncLive
1
INBRX-106 Plus Pembrolizumab Improves Responses and PFS in First-Line PD-L1–Positive HNSCC
2
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
3
‘Our Impact Will Be Broad and Transformative’: Wells Messersmith, MD, Takes the Reins at CU Anschutz Cancer Center
4
AUA Releases Guideline Amendment for NMIBC
5